Vaxart (VXRT) Stock Rockets On FDA Approval To Begin COVID-19 Vaccine Trials

Vaxart VXRT Stock News

Vaxart Inc (NASDAQ: VXRT) is screaming for the top in the market this morning, trading on early gains of more than 14%. The gains come after the company said that it has received the nod to move forward with in-human trials of its oral COVID-19 vaccine. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VXRT Rockets On Coming COVID-19 Clinical Trial

In the press release, Vaxart said that the United States Food and Drug Administration has completed its review of the company’s Investigational New Drug Application. The application surrounds a Phase 1 clinical trial that will evaluate the company’s oral COVID-19 vaccine candidate.

VXRT also provided an update with regard to its COVID-19 program. In the update, the company pointed to positive data from animal studies of the vaccine and the approval from the FDA to move forward with human trials as major recent accomplishments.

In a statement, Andrei Floroiu, CEO at VXRT, had the following to offer:

Our goal is to deliver the best, most elegant solution for conferring mass protection against COVID-19. Our oral tablet vaccine offers a much more attractive mode of administration than injectables and may confer superior protection against COVID-19 due to activation of mucosal immunity. Importantly, our room-temperature stable tablet is significantly easier and cheaper to store and distribute to the farthest corners of the US and the globe, as it does not require the very costly and complex refrigerated cold chain needed for injectable vaccines.

The IND clearance and the initiation of our Phase 1 clinical trial moves us a step closer to proving the superiority of our convenient oral COVID-19 solution in the clinic. We are thus excited to start enrollment for our Phase 1 this month.

This News Is Huge

The news released by Vaxart today is overwhelmingly positive. There are a few things to keep in mind here. First and foremost, the company’s COVID-19 vaccine candidate is the first oral vaccine candidate to reach human clinical trials. With all other vaccines requiring the use of needles, if this is as effective, or proves to be more effective in other options during its clinical trials, it could become the standard in vaccinating against this deadly virus.

Moreover, there have been some that argue that with vaccines coming early this year, companies that are not already in late stages will miss the train. I highly disagree with this idea.

The fact of the matter is that COVID-19 is caused by a coronavirus. These strains of viruses or incredibly hardy, and a single vaccine isn’t likely to work for everyone. Moreover, there is a large population of consumers that refuse vaccines. Going one step further we find that coronavirus immunity doesn’t last forever, that’s why you deal with the common cold multiple times throughout your life.

Given these facts, I believe that COVID-19 will become a seasonal issue that requires multiple vaccine and therapeutic options to keep under control for the long term. As a result, VXRT has plenty of time to turn their COVID-19 vaccine candidate into a profitable product.

As a result, if you’re not watching VXRT stock yet, you should be.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.